Skip to main content

Research Repository

Advanced Search

Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer

Sabra, Rayan; Billa, Nashiru; Roberts, Clive J.

Authors

Rayan Sabra

Nashiru Billa



Abstract

© 2019 Elsevier B.V. In the present study, we successfully developed a cetuximab-conjugated modified citrus pectin-chitosan nanoparticles for targeted delivery of curcumin (Cet-MCPCNPs) for the treatment of colorectal cancer. In vitro analyses revealed that nanoparticles were spherical with size of 249.33 ± 5.15 nm, a decent encapsulation efficiency (68.43 ± 2.4%) and a ‘smart’ drug release profile. 61.37 ± 0.70% of cetuximab was adsorbed to the surface of the nanoparticles. Cellular uptake studies displayed enhanced internalization of Cet-MCPCNPs in Caco-2 (EGFR +ve) cells, which ultimately resulted in a significant reduction in cancer cell propagation. The cell cycle analysis indicated that Cet- MCPCNPs induced cell death in enhanced percentage of Caco-2 cells by undergoing cell cycle arrest in the G2/M phase. These data suggest that Cet-MCPCNPs represent a new and promising targeting approach for the treatment of colorectal cancer.

Citation

Sabra, R., Billa, N., & Roberts, C. J. (2019). Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer. International Journal of Pharmaceutics, 572, Article 118775. https://doi.org/10.1016/j.ijpharm.2019.118775

Journal Article Type Article
Acceptance Date Oct 7, 2019
Online Publication Date Oct 31, 2019
Publication Date Dec 15, 2019
Deposit Date Aug 30, 2022
Journal International Journal of Pharmaceutics
Print ISSN 0378-5173
Electronic ISSN 1873-3476
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 572
Article Number 118775
DOI https://doi.org/10.1016/j.ijpharm.2019.118775
Public URL https://nottingham-repository.worktribe.com/output/3548526
Publisher URL https://www.sciencedirect.com/science/article/abs/pii/S0378517319308208?via%3Dihub